Pacira BioSciences Inc. (PCRX)
Levi & Korsinsky Announces an Investigation on Behalf of Pacira BioSciences, Inc. (PCRX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
Pacira (PCRX) Q3 Earnings Beat Estimates
Pacira (PCRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.72 per share a year ago.
Pacira's Exparel Receives Permanent New Product-Specific J-Code
PCRX reports that the CMS has assigned a permanent product-specific J-code for Exparel, which is set to facilitate better insurance coverage for the drug.
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
Pacira (PCRX) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by higher Exparel sales.
Pacira BioSciences, Inc. (PCRX) Q2 2024 Earnings Call Transcript
Pacira BioSciences, Inc. (PCRX) Q2 2024 Earnings Call Transcript
Pacira (PCRX) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
Pacira (PCRX) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.78 per share a year ago.
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
